发明申请
- 专利标题： HEPATITIS B ANTIVIRAL AGENTS
-
申请号： US16194608申请日： 2018-11-19
-
公开(公告)号： US20190084994A1公开(公告)日： 2019-03-21
- 发明人: Yao-Ling Qiu , Xuri Gao , Wei Li , Hui Cao , Meizhong Jin , Jorden Kass , Xiaowen Peng , Yat Sun Or
- 申请人： ENANTA PHARMACEUTICALS, INC.
- 主分类号： C07D493/08
- IPC分类号： C07D493/08 ; C07D493/04 ; C07D451/04 ; C07D401/04 ; C07D327/10 ; C07D317/72 ; C07D313/04 ; C07D309/08 ; C07D307/33 ; C07D307/32 ; C07D303/34 ; C07D303/26 ; C07D295/088 ; C07D277/26 ; C07D263/52 ; C07D261/20 ; C07D261/08 ; C07D261/02 ; C07D257/04 ; C07D233/64 ; C07D231/12 ; C07D213/89 ; C07D213/81 ; C07D213/52 ; C07D211/54 ; C07D207/16 ; C07C235/56 ; C07B59/00 ; C07C323/62 ; C07C317/44 ; C07C323/42 ; C07C317/32 ; C07C311/53 ; A61K31/655 ; A61K31/5377 ; A61K31/4545 ; A61K31/445 ; A61K31/4425 ; A61K31/4409 ; A61K31/4402 ; A61K31/44 ; A61K31/439 ; A61K31/426 ; A61K31/421 ; A61K31/4164 ; A61K31/416 ; A61K31/415 ; A61K31/41 ; A61K31/401 ; A61K31/39 ; A61K31/365 ; A61K31/357 ; A61K31/351 ; A61K31/341 ; A61K31/336 ; A61K31/335 ; A61K31/325 ; A61K31/277 ; A61K31/223 ; A61K31/215 ; A61K31/196 ; A61K31/18 ; A61K31/167
摘要：
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
公开/授权文献
- US10538532B2 Hepatitis B antiviral agents 公开/授权日：2020-01-21
信息查询
